DOACs in elective electrical cardioversion 29 investigations of antihemostatic medicinal products in non-surgical patients, J. Thromb. Haemost. 3 (4) (2005) 692–694. 20. J.C. van Swieten, P.J. Koudstaal, M.C. Visser, H.J. Schouten, J. van Gijn, Interobserver agreement for the assessment of handicap in stroke patients, Stroke. 19 (5) (1988) 604–607. 21. M.L. Hansen, R.M. Jepsen, J.B. Olesen, et al., Thromboembolic risk in 16 274 atrial fibrillation patients undergoing direct current cardioversion with and without oral anticoagulant therapy, Europace. 17 (1) (2015) 18–23. 22. A. Goette, H. Heidbuchel, Practical implementation of anticoagulation strategy for patients undergoing Cardioversion of atrial fibrillation, Arrhythmia Electrophysiol. Rev. 6 (2) (2017) 50–54. 23. L.A. de Jong, M. Koops, J.J. Gout-Zwart, et al., Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference, Neth. J. Med. 76 (10) (2018) 426–430. 24. V. Ten Cate, H. Ten Cate, F.W. Verheugt, The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) : Exploring the changes in anticoagulant practice in patients with nonvalvular atrial fibrillation in the Netherlands, Neth. Hear. J. 24 (10) (2016) 574–580. 25. S.H. Hohnloser, R. Cappato, M.D. Ezekowitz, et al., Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial, Europace. 18 (2) (2016) 184–190. 26. C.M. Gibson, A.N. Basto, M.L. Howard, Direct Oral anticoagulants in Cardioversion: a review of current evidence, Ann. Pharmacother. 52 (3) (2018) 277–284. 27. S.A. Di Fusco, F. Colivicchi, N. Aspromonte, M. Tubaro, A. Aiello, M. Santini, Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials, Monaldi Arch. Chest Dis. 87 (1) (2017) 805. 28. R.I. Mincu, A.A.Mahabadi,M. Totzeck, T. Rassaf, Novel anticoagulants versus vitamin K antagonists for cardioversion of non- valvular atrial fibrillation – a meta-analysis of more than 17000 patients, Sci. Rep. 9 (1) (2019) 3011. 29. E. Bertaglia, M. Anselmino, A. Zorzi, et al., NOACs and atrial fibrillation: incidence and predictors of left atrial thrombus in the real world, Int. J. Cardiol. 249 (2017) 179–183. 30. G. Stabile, V. Russo, A. Rapacciuolo, et al., Transesophageal echocardiograpy in patients with persistent atrial fibrillation undergoing electrical cardioversion on new oral anticoagulants: a multi center registry, Int. J. Cardiol. 184 (2015) 283–284. 2
RkJQdWJsaXNoZXIy MTk4NDMw